Cargando…
Immunotherapies in ovarian cancer
Ovarian cancer is the leading cause of death for gynaecological cancer, and new therapies are urgently awaited. Although the presence of tumour-infiltrating lymphocytes has been confirmed to be associated to a better prognosis, immunotherapy is not yet incorporated to the armamentarium in ovarian ca...
Autores principales: | García-Martínez, Elena, Pérez-Fidalgo, J. Alejandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573463/ https://www.ncbi.nlm.nih.gov/pubmed/33240447 http://dx.doi.org/10.1016/j.ejcsup.2020.02.002 |
Ejemplares similares
-
Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?
por: García-Martínez, Elena, et al.
Publicado: (2020) -
Aurora kinases in ovarian cancer
por: Pérez-Fidalgo, J Alejandro, et al.
Publicado: (2020) -
NOTCH signalling in ovarian cancer angiogenesis
por: Perez-Fidalgo, Jose Alejandro, et al.
Publicado: (2020) -
Immunotherapy in Ovarian Cancer
por: Siminiak, Natalia, et al.
Publicado: (2022) -
Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus
por: Redondo, Andrés, et al.
Publicado: (2023)